Peter Attia on TRT: separating signal from supplement hype

What did @diaryofaceohub actually say?

The clip presents Peter Attia arguing that TRT, when used responsibly, is "a very low risk proposition that comes with many benefits." He specifically addresses two historical fears: that testosterone raises prostate cancer risk and cardiovascular disease risk. His position is that both concerns have "not borne out" at physiologic doses. That's a fairly strong claim, and it deserves a close look rather than automatic applause or dismissal.

Attia is a physician with a significant public following, and his views carry weight with the men who watch this kind of content. The framing here is reassuring, which is fine if the evidence supports it, and largely, though not entirely, it does.

Does the science back this up?

On prostate cancer, Attia is mostly right. The long-standing fear traced back to Charles Huggins' 1941 work linking androgen deprivation to prostate cancer regression. For decades, doctors assumed the reverse was equally true. It isn't. The "saturation model" proposed by Morgentaler and Traish (2009, European Urology) offers a more accurate picture: prostate tissue becomes saturated with testosterone at relatively low concentrations, and adding more doesn't meaningfully increase cancer risk in men with normal prostates.

The cardiovascular story is messier. The TRAVERSE trial (Lincoff et al., 2023, New England Journal of Medicine), a large randomized controlled trial of over 5,200 men with hypogonadism and elevated cardiovascular risk, found that testosterone replacement was non-inferior to placebo for major adverse cardiac events. That's genuinely reassuring. However, the trial also found increased rates of atrial fibrillation, pulmonary embolism, and acute kidney injury in the testosterone group. Attia's claim that cardiovascular risk hasn't "borne out" is accurate at the headline level but skips over these secondary findings.

What did they get wrong (or right)?

Credit where it's due: the blanket fear that TRT causes heart attacks or feeds prostate cancer is not supported by current evidence. Attia is correct on both counts at a broad level, and saying so publicly is useful given how much misinformation circulates in both directions on this topic.

What's missing is nuance. "Physiologic doses" is doing a lot of work in that sentence. The difference between replacing testosterone to normal range in a genuinely hypogonadal man and pushing levels to the high end of normal, or above it, matters clinically. The TRAVERSE trial specifically studied men with confirmed hypogonadism. Extrapolating that safety data to men using TRT for optimization without documented deficiency is a stretch the evidence doesn't currently support.

The secondary findings from TRAVERSE, including a roughly 30% relative increase in atrial fibrillation risk, aren't trivial. For a man with existing cardiac conduction issues, that's a real conversation to have with a doctor, not a footnote.

What should you actually know?

TRT is a legitimate medical treatment for men with clinically confirmed low testosterone, defined by both symptoms and blood work, not just a desire to feel better or build muscle faster. The safety profile at true physiologic replacement doses is more favorable than older guidelines suggested, and the medical consensus has shifted accordingly.

But "low risk" is not "no risk." Polycythemia (elevated red blood cell count) is a well-documented side effect that increases clotting risk if hematocrit isn't monitored. Fertility suppression is real and often irreversible without intervention. Testicular atrophy occurs with exogenous testosterone because the HPG axis suppresses endogenous production.

If you're considering TRT because of a TikTok clip, that's a starting point, not an endpoint. A proper evaluation includes total testosterone, free testosterone, LH, FSH, prolactin, and a symptom review. A number alone doesn't tell the full story, and neither does a 30-second video.